TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tango Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$23.53+1.49 (+6.76%)
Close on Oct 19, 2026
- Market cap
- $3.53B
- P/E (TTM)
- –
- Dividend yield
- –
Tango Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Tango Therapeutics | Industry median |
|---|---|---|
| Market Cap | $3.97B | $166.30M |
| Enterprise Value | $2.97B | $87.12M |
| PS Ratio | 73.73 | 3.60 |
| PB Ratio | 3.87 | 2.03 |
| P/TBV Ratio | 3.87 | 2.31 |
Enterprise value
| Measure | Tango Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 55.14 | 2.43 |
Income (trailing twelve months)
| Measure | Tango Therapeutics | Industry median |
|---|---|---|
| Revenue | $53.81M | $57.94M |
| Operating Income | -$136.35M | -$21.49M |
| Pretax Income | -$123.78M | -$14.72M |
| Net Income | -$123.72M | -$22.46M |
| EBITDA | -$136.35M | -$17.14M |
| EPS (Diluted) | -$0.85 | -$0.83 |
Margins
| Measure | Tango Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -253.4% | -44.5% |
| Pretax Margin | -230.0% | -13.0% |
| Profit Margin | -229.9% | -39.2% |
| EBITDA Margin | -253.4% | -31.3% |
| FCF Margin | -268.1% | -8.85% |
Returns
| Measure | Tango Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -21.3% | -53.2% |
| Return on Assets (ROA) | -18.9% | -41.0% |
| Return on Capital Employed (ROCE) | -12.9% | -38.0% |
Growth
| Measure | Tango Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 121.5% | 6.01% |
| Revenue Growth (3Y CAGR) | 35.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 52.1% | 6.42% |
Balance sheet
| Measure | Tango Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.00B | $62.64M |
| Net Cash (Debt) | $1.00B | $15.77M |
| Net Cash Per Share | $5.93 | $0.66 |
| Equity (Book Value) | $1.02B | $48.61M |
| Book Value Per Share | $6.08 | $1.36 |
| Tangible Book Value | $1.02B | $23.01M |
| Working Capital | $1.01B | $75.09M |
Financial position
| Measure | Tango Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 50.82 | 3.30 |
| Quick Ratio | 49.26 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Tango Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$143.90M | -$12.39M |
| Capital Expenditures | -$351.00K | -$1.07M |
| Free Cash Flow | -$144.25M | -$20.34M |
| FCF Per Share | -$0.86 | -$0.42 |
Efficiency
| Measure | Tango Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.08 | 0.38 |
| Revenue Per Employee | $392.78K | $398.96K |
| Profits Per Employee | -$903.07K | -$705.27K |
| Employee Count | 137 | 74 |
Dividends and yields
| Measure | Tango Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -3.12% | -22.8% |
| FCF Yield | -3.64% | -9.02% |
Shares
| Measure | Tango Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 168,610,000 | 58,139,000 |
| Shares Change (YoY) | 23.7% | 11.1% |
| Shares Change (QoQ) | 16.8% | 0.54% |
| Float | 134,487,000 | 49,154,900 |
| Shares Held by Insiders | 20.2% | 11.6% |
| Shares Held by Institutions | 127.3% | 59.4% |
Taxes
| Measure | Tango Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$63.00K | $89.00K |
Scores
| Measure | Tango Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 48.08 | -0.27 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Tango Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.